Mya Hall, in Hernando, MS - Counselor

Mya Hall, is a Counselor - Mental Health based in Hernando, Mississippi. Mya Hall is licensed to practice in * (Not Available) (license number ) and her current practice location is 2705 Highway 51 S, Hernando, Mississippi. She can be reached at her office (for appointments etc.) via phone at (662) 449-1971.

NPI number for Mya Hall is 1184297715 and her current mailing address is 2705 Highway 51 S, Hernando, Mississippi. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1184297715.

Contact Information

	Mya Hall,
	2705 Highway 51 S, Hernando, MS 38632-2634
	(662) 449-1971
	Not Available

Healthcare Provider's Profile

Full Name	Mya Hall
Gender	Female
Speciality	Counselor - Mental Health
Location	2705 Highway 51 S, Hernando, Mississippi
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1184297715
Provider Enumeration Date: 07/21/2021
Last Update Date: 07/21/2021

Medical Identifiers

Medical identifiers for Mya Hall such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1184297715	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
101YM0800X	Counselor - Mental Health	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mya Hall is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mya Hall, 2705 Highway 51 S, Hernando, MS 38632-2634 Ph: () -	Mya Hall, 2705 Highway 51 S, Hernando, MS 38632-2634 Ph: (662) 449-1971

News Archive

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

Tarvacin shows significant anti-viral activity

Peregrine Pharmaceuticals today announced that there will be two presentations, April 4 and 6, at the American Association of Immunologists (AAI) annual meeting in San Diego, California, indicating the anti-viral potential of its Tarvacin antibody. Dr. Melina Soares of The University of Texas Southwestern Medical Center at Dallas will present pre-clinical data titled "Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever."

Medicaid expansions could spell trouble for states, Democrats in Congress

Rising health costs, growing numbers of Medicaid enrollees and the possibility of a new mandate to increase the income threshold to become eligible for the program are combining to put state's governors, as well as Democrats in Congress in sometimes awkward positions.

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to placebo plus insulin (with or without OADs).

Scientist develop compact, portable sanitizing device for masks and other items

COVID-19 has significantly increased public use of face masks to protect others from the wearer's respiratory droplets as well as the wearer from airborne contaminants.

Counselor in Hernando, MS

Paul Marty Forsythe, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2705 Highway 51 S, Hernando, MS 38632 Phone: 662-449-1971 Fax: 662-449-1974
Kamela Duncan, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 324 W Valley St, Suite 108, Hernando, MS 38632 Phone: 901-488-1107 Fax: 662-788-1585
Diamond Santiago Fairley, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2705 Highway 51 S, Hernando, MS 38632 Phone: 662-449-1808
Dawn M. Flanagan, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2705 Highway 51 S, Hernando, MS 38632 Phone: 662-449-1971 Fax: 662-449-1974
Raneshia N Lee, MSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 2725 Highway 51 S, Hernando, MS 38632 Phone: 662-449-1808 Fax: 662-449-1811
Jeremy Schrimsher, MA Counselor Medicare: Not Enrolled in Medicare Practice Location: 2725 Highway 51 S, Hernando, MS 38632 Phone: 662-449-1808
Rochelle Laquita Mcgee, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2725 Hwy 51 South, Hernando, MS 38632 Phone: 662-449-1808 Fax: 662-449-1811

Mya Hall, - Counselor in Hernando, MS